Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21793669 | 0.83 | KMT2A (0.55) | RAB9AL3MBTL1NPC1SMN1; SMN2KDM4E | |
| SCHEMBL1631363 | 0.81 | P2RX7 (0.51) | RAB9AL3MBTL1ALDH1A1P2RX7 | |
| SCHEMBL21794795 | 0.79 | NPC1 (0.60) | RAB9AL3MBTL1NPC1SMN1; SMN2KDM4E | |
| SCHEMBL4414649 | 0.78 | RAB9A (0.65) | RAB9AL3MBTL1NPC1CYP19A1SMN1; SMN2 | |
| SCHEMBL4413954 | 0.78 | RAB9A (0.65) | RAB9AL3MBTL1NPC1CYP19A1SMN1; SMN2 | |
| SCHEMBL4409125 | 0.78 | RAB9A (0.59) | RAB9AL3MBTL1NPC1CYP19A1SMN1; SMN2 | |
| SCHEMBL12359857 | 0.78 | TSHR (0.44) | RAB9AL3MBTL1NPC1CYP19A1SMN1; SMN2 | |
| SCHEMBL31273014 | 0.78 | MAPT (0.46) | RAB9AL3MBTL1NPC1TSHRALDH1A1 | |
| SCHEMBL2326678 | 0.77 | RAB9A (0.62) | RAB9AL3MBTL1NPC1CYP19A1SMN1; SMN2 | |
| SCHEMBL4413466 | 0.77 | RAB9A (1.00) | RAB9AL3MBTL1NPC1SMN1; SMN2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865195-B2 | Pet imaging agents | NOVARTIS AG (CH) | 2020-12-15 | — | — | US | disclosed |
| CN-107406419-B | PET imaging agent | 诺华股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-10450298-B2 | PET Imaging agents | NOVARTIS AG (CH) | 2019-10-22 | — | — | US | disclosed |
| US-20180273509-A1 | PET Imaging Agents | NOVARTIS AG (CH) | 2018-09-27 | — | — | US | disclosed |
| EP-3247706-A1 | PET IMAGING AGENTS | Novartis AG (CH) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016116875-A1 | PET IMAGING AGENTS | NOVARTIS AG (CH) | 2016-07-28 | — | — | WO | disclosed |
| US-8071565-B2 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-8071565-B2 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-20100240680-A1 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240680-A1 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-1859782-B1 | Composition for coloring and/or lightening human hair comprising tetrazoles | HENKEL AG & CO KGAA (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20090035271-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| WO-2008129129-A1 | HETEROCYCLIC PHENYL CARBAMATES AS NOVEL FAAH-INHIBITORS | KUOPION YLIOPISTO (FI) | 2008-10-30 | — | — | WO | disclosed |
| EP-1889846-A1 | Purine derivatives as A2a agonists | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2008019289-A2 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| EP-1859782-A1 | Composition for coloring and/or lightening human hair comprising tetrazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007125398-A2 | : SULFONAMIDE COMPOUNDS AS ANTAGONISTS OF THE N-TYPE CALCIUM CHANNEL | PFIZER JAPAN INC. (JP) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035271-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS4, PRSS1, SPINT2 | RAB9A 3922/4885L3MBTL1 3365/4885NPC1 314/4885 |
| US-10450298-B2 | PET Imaging agents | ENPP2, EPX, MAN2B1 | RAB9A 1493/4885L3MBTL1 3517/4885NPC1 1897/4885 |
| US-20100240680-A1 | Purine derivatives as a2a agonists | ADORA2A, ADORA1, ADORA3 | RAB9A 2137/4885L3MBTL1 4045/4885NPC1 2015/4885 |
| US-10865195-B2 | Pet imaging agents | ENPP2, EPX, MAN2B1 | RAB9A 1493/4885L3MBTL1 3517/4885NPC1 1897/4885 |
| US-20180273509-A1 | PET Imaging Agents | ENPP2, EPX, MAN2B1 | RAB9A 1493/4885L3MBTL1 3517/4885NPC1 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.